This trial will test if a drug called duvelisib is safe and effective in treating T-cell lymphomas.
- T-Cell Lymphoma
- Indolent B Cell Non-Hodgkin Lymphoma
1 Primary · 4 Secondary · Reporting Duration: 2 years
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
36 Total Participants · 1 Treatment Group
Primary Treatment: Duvelisib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does this experiment constitute a pioneering endeavor?
"Presently, Secura Bio, Inc. is running 16 trials for Duvelisib in cities across 8 nations. This series of clinical studies began in 2014 with a Phase 1 & 2 trial hosting 32 participants and has since concluded 15 further experiments." - Anonymous Online Contributor
Is this medical study currently accepting new participants?
"Data from clinicaltrials.gov demonstrates that recruitment for this trial is still in process. It was first announced on July 23rd 2020, and the most recent update occurred on July 18th 2022." - Anonymous Online Contributor
What precautions should patients take when being prescribed Duvelisib?
"Our team has determined that duvelisib is relatively safe, receiving a score of 2 on our grading system. This is because it's currently in Phase 2 trials which have yielded some data regarding safety but not efficacy." - Anonymous Online Contributor
To what maladies is Duvelisib typically prescribed?
"Duvelisib is frequently administered to patients with refractory, relapsed small lymphocytic lymphoma. It may also be used in therapeutic procedures and as a last-line treatment for refractory anemias following two prior therapies." - Anonymous Online Contributor
How many individuals has this research enrolled thus far?
"Affirmative. According to the information stored on clinicaltrials.gov, this research trial is presently accepting participants; it was first posted on July 23rd 2020 and last updated on July 18th 2022. The study requires 36 patients from 1 site only." - Anonymous Online Contributor
What precedent has been set with regard to Duvelisib-based research?
"Currently, 16 studies are being conducted to further investigate the efficacy of Duvelisib. None of these active trials is in Phase 3 yet. The majority of research for this drug takes place in Boston, MA but there are 147 clinical sites across the world researching it as well." - Anonymous Online Contributor